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Abstract
Mutations in the gene for parkin, a 52-kDa E3 ubiquitin ligase, are a major cause of hereditary Parkinson’s disease (PD). In vitro
studies have identiﬁed a large number of parkin-interacting proteins. Whether parkin exists as a monomer or as part of a stable
protein complex in vivo is uncertain. Here we demonstrate that endogenous parkin occurs in a stable, non-covalent,  110-kDa
complex in native extracts from mouse brain, heart and skeletal muscle, while monomeric parkin is undetectable. Partial denaturation
experiments indicate that this complex is at least a tetramer. Reported parkin-binding partners do not show detectable association
with the parkin complex on native gels. Upon overexpression in COS1, SH-SY5Y or CHO cells, parkin accumulates predominantly as
a monomer, suggesting that the interactors required for complex formation are available in limiting amounts in these cells.
Importantly, PD-linked parkin mutations signiﬁcantly impair parkin complex formation. These data demonstrate that parkin
oligomerizes into a stable, non-covalent, heteromeric complex in vivo, and suggest that parkin may have as yet unidentiﬁed stable
binding partners.
Introduction
Parkin mutations are among the most common causes of familial
Parkinson’s disease (PD), accounting for approximately 50% of early
onset autosomal recessive cases (Kitada et al., 1998; Lu ¨cking et al.,
2000). Parkin is a cytosolic, 52-kDa E3 ubiquitin ligase responsible
for targeting speciﬁc substrates for proteasomal degradation (Imai
et al., 2000; Shimura et al., 2000; Zhang et al., 2000). A variety of
PD-linked parkin mutations have been shown to induce a loss of
parkin function through direct catalytic impairment or by decreasing
parkin solubility or stability (Henn et al., 2005; Sriram et al., 2005).
Thus, pathogenic parkin mutations could cause neurodegeneration
through a toxic accumulation of one or more parkin substrates.
However, other PD-linked parkin mutations have no discernible
impact on the intrinsic ubiquitin ligase activity, solubility or other
biochemical properties of parkin (Hampe et al., 2006), and the
pathogenic mechanism of these mutations remains unknown.
A large number of putative parkin substrates have been reported,
including cell division control-related protein 1 (CDCrel-1; Zhang
et al., 2000), synphilin-1 (Chung et al., 2001), parkin-associated
endothelin receptor-like receptor (Pael-R; Imai et al., 2001),
O-glycosylated a-synuclein (Shimura et al., 2001), a⁄b-tubulin
(Ren et al., 2003), cyclin E (Staropoli et al., 2003), the p38 subunit
of the aminoacyl-tRNA synthetase complex (Corti et al., 2003),
the nuclear membrane-associated protein Ras-related nuclear small
G-protein-binding protein 2 (RanBP2; Um et al., 2006) and ataxin-2
(Huynh et al., 2007). Importantly, parkin may also ubiquitinate
substrates in proteasome-independent pathways (Lim et al., 2005),
as recently shown for epidermal-growth-factor receptor pathway
substrate clone (Eps15; Fallon et al., 2006), tumour necrosis factor
receptor-associated factor 2 (TRAF2) and IjB kinase c (IKKc; Henn
et al., 2007).
In addition to binding transiently to substrates, parkin may also
interact more stably with non-substrate-binding partners. For example,
binding of parkin to C-terminus of heat shock protein 70 (Hsp70)-
interacting protein (CHIP) has been reported to enhance the ubiquitin
ligase activity of parkin (Imai et al., 2002). Conversely, parkin activity
is inhibited by interaction with bcl-2-associated athanogene 5 (BAG5;
Kalia et al., 2004) or with the chaperones Hsp70 (Imai et al., 2002) or
14-3-3g (Sato et al., 2006). According to a different study parkin
functions in a multiprotein ubiquitin ligase complex including the
F-box protein hSel-10 and cullin-1 (Staropoli et al., 2003). In this
complex hSel-10, rather than parkin itself, would be responsible for
substrate recognition. Association with calcium⁄calmodulin-depen-
dent serine protein kinase (CASK) may localize parkin to the synapse
(Fallon et al., 2002), while interaction with a⁄b tubulin may anchor
parkin to microtubules (Yang et al., 2005). Parkin may associate with
the E2 enzyme ubiquitin-conjugating human enzyme 7 (UbcH7; Imai
et al., 2000; Shimura et al., 2001), or may be attached to the
proteasome through interactions with the proteasomal subunits
regulatory particle non-ATPase 10 (Rpn10; Sakata et al., 2003) or
XAPC7 (Dachsel et al., 2005). Finally, parkin has also been reported
to interact with DJ-1 (Baulac et al., 2004) and leucine-rich repeat
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familial PD.
Many of the reported parkin interactions were identiﬁed through
in vitro assays, such as yeast-two-hybrid studies, and the in vivo
signiﬁcance of these interactions is uncertain. Whether parkin exists as
a monomer or as part of a stable protein complex in the brain remains
unknown. Here we address this question using velocity gradient
centrifugation, blue native-polyacrylamide gel electrophoresis
(BN-PAGE) and gel ﬁltration chromatography.
Materials and methods
Antibodies
Polyclonal rabbit anti-parkin antibody (CS2132) was from Cell
Signalling Technology; monoclonal parkin antibodies PRK8 and
PRK109 (Pawlyk et al., 2003) were a kind gift from Dr Virginia Lee
(University of Pennsylvania); rabbit anti-CUL1 and rabbit anti-CASK
were from Zymed; rabbit anti-hSel-10 (anti-hCdc4, 69-kDa isoform)
was from Gentaur Molecular Products; mouse antibodies against
CDCrel-1, UbcH7 and a-synuclein were from BD Transduction
Laboratories; rabbit anti-Hsp70 was from Stressgen; polyclonal goat
anti-DJ-1, rabbit anti-IKKc (FL-419) and rabbit anti-TRAF2 (C-20)
were from Santa Cruz Biotechnology; rabbit anti-BAG5 was from
Exalpha Biologicals; mouse anti-a-tubulin was from Sigma; rabbit
anti-a-tubulin and anti-b-tubulin and goat anti-synphilin-1 were from
Abcam; rabbit anti-CHIP was from Calbiochem; rabbit anti-Rpn10
(anti-PSMD4) was from Abgent; rabbit anti-14-3-3g was from IBL;
mouse anti-XAPC7 was from Biotrend; rabbit anti-p38 was a kind gift
from Dr S. Kim (Seoul National University); and puriﬁed rabbit IgG
was from Chemicon.
Tissue extraction, glycerol gradient centrifugation
and BN-PAGE
All the steps of tissue preparation, glycerol gradient centrifugation and
BN-PAGE were performed at 4  C. Brain stem and diencephalon, heart
or skeletal muscle were dissected from 2- to 4-month-old wild-type
(C57⁄Bl6J) or parkin-null (Itier et al., 2003) mice after decapitation.
Procedures followed were approved by the ethical committee of the
University of Leuven. The tissue was homogenized with a glass pestle
in 10 volumes of 20 mm Tris-HCl, pH 7.4, followed by trituration
through a 200-lL pipette tip. The homogenization buffer did not
contain salts, because salts may lead to precipitation of Coomassie dye
and stained proteins on BN gels (Scha ¨gger et al., 1994; Vandenberghe
et al., 2005a). Homogenates were centrifuged at 200 g for 5 min,
followed by an additional 5 min spin at 350 g (Fig. 1A). Control
experiments indicated that the pellets obtained after the 200 g and
350 g centrifugation steps did not contain a signiﬁcant amount of
parkin (Fig. 1B). The supernatant obtained after the 350 g spin was
centrifuged at 20 000 g for 2 min, leading to separation of pellet (P)
and supernatant (S) fractions. P was resuspended in 10 volumes of 1%
TritonX-100⁄20 mm Tris, pH 7.4. Triton X-100was alsoaddedto S to
a ﬁnal concentration of 1%. After incubation for 30 min the samples
were centrifuged at 20 000 g for 5 min. To test whether parkin was
fully extracted in 1% Triton X-100, the pellets remaining after the ﬁnal
20 000 gspinweresolubilizedin1.5%sodiumdodecylsulphate(SDS)
at 100  C for 10 min. However, SDS–PAGE and Western blot with
PRK8 did not detect any parkin in this Triton X-100-resistant, SDS-
extractable fraction (data not shown). Protein concentrations of the
Triton X-100 extracts were determined for P and S with the Bio-Rad
Protein assay. Approximately 2 mg of protein extract was layered onto
10–50% glycerol gradients. Gradients were centrifuged in a SW-55
rotor (Beckman) at 4  C for 18 h at 165 000 gav (Vandenberghe et al.,
2005a). Twelve fractions of 450 lL were collected manually from the
top, and 90 lL of each fraction was loaded on BN gels. BN-PAGE and
immunoblotting were performed as previously described in detail
(Vandenberghe et al., 2005a), except that 4–20% gradient gels were
used in the present study. Immunoreaction was visualized with ECL or
ECL Plus (Pierce), and exposure of the membrane to Kodak X-OMAT
ﬁlm. Antibody supershift experiments were performed as previously
described (Yang et al., 2002; Vandenberghe et al., 2005a).
Gel ﬁltration chromatography
Approximately 1 mg of S fraction, prepared as described above except
that Triton X-100 was omitted, was applied to a Superdex 200 HR
16⁄50 column (Pharmacia). The column was pre-equilibrated and
eluted with 50 mm NaCl⁄25 mm Tris-HCl, pH 7.4. Elution was at a
ﬂow rate of 1 mL⁄min at 4  C. Fractions of 0.5 mL were collected
and analysed with dot blot for parkin. Calibration standards, including
thyroglobulin (669 kDa), ferritin (440 kDa), lactate dehydrogenase
Fig. 1. Tissue extraction, glycerol gradient centrifugation and blue-native-
polyacrylamide gel electrophoresis (BN-PAGE) procedure. (A) Sche-
matic overview of the procedure. (B) Mouse brain stem and diencephalon
were homogenized as described in Materials and methods, and centrifuged at
350 g for 5 min. The pellet (Lane 1) and supernatant (Lane 2) obtained after the
350 g spin were compared for parkin content. SDS was added to the
supernatant at a ﬁnal concentration of 2%, and the pellet was resuspended in
2% SDS ⁄ 20 mm Tris, pH 7.4. After boiling for 10 min and centrifugation at
14 000 g for 5 min, 60 lg of protein extract was loaded in each lane and
examined by SDS–PAGE and Western blotting with the monoclonal anti-parkin
antibody PRK109. The mobility of a 50-kDa molecular weight marker is shown
on the left of the blot.
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protein (55 kDa) and protein phosphatase 2A phosphatase activator
(36 kDa) were separated on the column under the same conditions and
detected by UV light detection at 280 nm.
Cell cultures and transfection
COS1 cells were cultured as previously described for COS7 cells
(Vandenberghe et al., 2005b). CHO and HEK-293 cells were cultured
in a 1 : 1 mix of Dulbecco’s modiﬁed Eagle medium (DMEM) and
F-12 nutrient mixture (Invitrogen), supplemented with l-glutamine
(2.5 mm), HEPES (15 mm), non-essential amino acids (1%), penicil-
lin (100 U⁄mL), streptomycin (100 lg⁄mL) and 10% foetal calf
serum. SH-SY5Y cells were cultured in a 1 : 1 mix of DMEM and
F-12 nutrient mixture, supplemented with l-glutamax (4 mm),
non-essential amino acids (1%), penicillin (100 U⁄mL), streptomycin
(100 lg⁄mL) and 15% foetal calf serum. COS1, CHO and HEK-293
cells were transiently transfected using Lipofectamine Plus (Invitro-
gen), as previously described for COS7 cells (Vandenberghe et al.,
2005b). We transfected 80 ng of cDNA per cm
2 of COS1, CHO or
HEK-293 cell culture, unless otherwise indicated. SH-SY5Y cells
were transiently transfected with the Nucleofector system (Amaxa)
using the T16 program according to the instructions of the manu-
facturer. Human wild-type parkin cDNA was kindly provided by
Dr K. Winklhofer (Max-Planck-Institute for Biochemistry, Martinsried,
Germany; Winklhofer et al., 2003). In experiments comparing wild-
type and pathogenic parkin variants, COS1 cells were transfected with
cDNAs encoding HA-tagged versions of wild-type, A82E, K161N,
K211N, R256C and R275W parkin. The cDNAs for these HA-tagged
parkin versions were constructed as previously described (Hampe
et al., 2006). Under the transfection conditions used in this study,
phase-contrast microscopy immediately before cell harvest revealed
no observable toxicity of COS1 cells expressing wild-type or
PD-linked parkin versions (not shown). This was conﬁrmed by
SDS–PAGE and Western blot experiments showing similar b-tubulin
levels in COS1 cells transfected with the different parkin variants (not
shown), thus assuring similar amounts of cellular input material. Two
days after COS1, CHO and HEK-293 cell transfection, and 24 h after
SH-SY5Y cell transfection, the medium was aspirated and the cells
were washed in ice-cold phosphate-buffered saline (PBS). The cells
were removed from the plate with a cell scraper, resuspended in 1%
Triton X-100⁄20 mm Tris, and solubilized for 30 min at 4  C.
Insoluble material was removed by centrifugation at 20 000 g for
5 min. Total protein concentrations of the Triton X-100 extracts were
determined with the Bio-Rad Protein assay, and 500 lg of protein
extract was layered onto 10–50% glycerol gradients. Glycerol gradient
centrifugation and BN-PAGE was performed in the same way as for
the brain extracts. In each of the glycerol gradient and BN-PAGE
experiments comparing parkin complex formation between wild-type
and pathogenic variants, we also compared the soluble levels of wild-
type and mutant parkin versions by parallel SDS–PAGE of 15 lgo f
the Triton-soluble protein extracts. After Western blotting, the density
of scanned signals was measured with UN-SCAN-IT gel 6.1 software
(Silk Scientiﬁc). For quantitative experiments, ﬁlm exposure times
below the saturation range were used, as determined by multiple
exposure times and as conﬁrmed by the UN-SCAN-IT saturation
check.
Production and puriﬁcation of recombinant parkin
GST-tagged wild-type parkin was produced in Escherichia coli, batch
puriﬁed with glutathione-Sepharose, eluted from the beads and
dialysed as previously described (Hampe et al., 2006). GST-parkin
was quantiﬁed by comparison with a bovine serum albumin standard
after SDS–PAGE and staining of the gel with Coomassie Blue,
aliquoted and stored at )80  C. To remove the GST tag, 2.5 lgo f
GST-parkin was again bound to glutathione-Sepharose for 1 h at 4  C
in 1% Triton X-100⁄PBS (pH 7.4). The glutathione-Sepharose-bound
GST-parkin was washed three times in 1% Triton X-100⁄PBS, and
three times in cleavage buffer (in mm: Tris-HCl, 50, pH 7.0; NaCl,
150; EDTA, 1; dithiothreitol, 1). GST-parkin was then cleaved on the
beads by incubation with 5 units PreScission Protease (Amersham) for
4 h at 5  C. Effective removal of the GST moiety was conﬁrmed by
determination of the molecular mass of recombinant parkin using
SDS–PAGE and Western blot (not shown).
Statistics
Statistical signiﬁcance of differences was analysed with one-way
anova and Student–Newman–Keuls test (SigmaStat 3.5, Systat).
Differences were considered signiﬁcant at P < 0.05. Values represent
mean ± SEM.
Results
Parkin is part of a stable, non-covalent,  110-kDa complex
in vivo
In contrast to SDS–PAGE, BN-PAGE is performed in non-denaturing
conditions and thus permits separation of intact non-covalent protein
complexes (Scha ¨gger et al., 1994; Vandenberghe et al., 2005a). We
used this technique to determine the native molecular mass of parkin
extracted from the brain stem and diencephalon of 2- to 4-month-old
mice. Brain homogenates were separated by centrifugation into pellet
(P) and supernatant (S) fractions (Fig. 1A). Fraction P was enriched in
membranes, as demonstrated by Western blotting for the a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor sub-
unit glutamate receptor subunit 2 (GluR2), a neuronal membrane
protein; fraction S was mostly cytosolic, as indicated by Western
blotting for the cytoplasmic protein a-tubulin (data not shown). After
incubation with 1% Triton X-100, solubilized proteins from fractions
P and S were further fractionated by centrifugation on 10–50%
glycerol gradients (Fig. 1A). The resulting fractions (P1–12 and
S1–12) were subjected to BN-PAGE followed by immunoblotting
with CS2132, a commonly used, commercially available polyclonal
anti-parkin antibody. This antibody detected a band in fraction S6 with
a very high molecular mass (450–550 kDa; Fig. 2A). To check the
speciﬁcity of the CS2132 antibody, we performed parallel experiments
on brain extracts from parkin-null mice. However, the 450–550-kDa
complex was equally detected in parkin-null extracts, indicating that it
was not an authentic parkin complex (Fig. 2A). The observed lack of
speciﬁcity of the CS2132 antibody was in agreement with the ﬁndings
of Pawlyk et al. (2003).
We therefore switched to using PRK8 and PRK109, two monoclo-
nal antibodies that were previously demonstrated to be parkin speciﬁc
(Pawlyk et al., 2003). These antibodies detected a single band
concentrated in fraction S5, which represented authentic parkin
because it was absent in parkin-null extracts (Fig. 2B). This native
parkin band had an estimated molecular mass of  110 kDa, based on
its mobility relative to native markers of known molecular mass
(Fig. 2C; Lee et al., 2002). A small amount of parkin of similar
molecular weight was detectable in fraction P5, but only after much
more prolonged ﬁlm exposure (data not shown). There was also some
minor immunoreactivity at higher molecular weights (asterisk in
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probably resulted from non-speciﬁc binding. Remarkably, monomeric
parkin was undetectable in native brain extracts (Fig. 2B). Importantly,
puriﬁed recombinant parkin had an apparent molecular mass of
 50 kDa on native gels (Fig. 2D), indicating that the  110-kDa
parkin band represented a protein complex rather than an unusual
tertiary conformation of the parkin monomer. Boiling brain extracts in
1.5% SDS for 10 min before BN-PAGE completely disassembled the
 110-kDa parkin complex and led to the appearance of monomeric
parkin (Fig. 2D), indicating that the parkin complex was held together
by non-covalent interactions.
In the experiments shown in Fig. 2A–C brain extracts were
solubilized in 1% Triton X-100. Although this is a mild detergent, we
wondered whether any parkin interactions might still be disrupted.
However, this was not the case, as shown by the fact that omission of
Triton X-100 from the extraction protocol did not affect the apparent
Fig. 2. BN-PAGE reveals a stable, non-covalent,  110-kDa parkin complex in brain. (A and B) Extracts of brain stem and diencephalon from wild-type and parkin
knockout (KO) mice were separated into pellet (P) and supernatant (S) fractions, as described in Materials and methods and Fig. 1A. P and S fractions were further
fractionated by glycerol gradient centrifugation. Twelve P and 12 S fractions (numbered from the top of the glycerol gradient to the bottom) were analysed by
BN-PAGE, followed by Western blotting with either the polyclonal anti-parkin antibody CS2132 (A) or the monoclonal anti-parkin antibody PRK109
(B). The CS2132 antibody detected a 450–550-kDa band in fraction S6, which was also found in parkin-null extract (A). By contrast, the PRK109 antibody (B)
revealed a band in fraction S5 at a lower molecular weight (indicated by the arrow), which was absent in parkin knockout brain. The PRK109 antibody also showed
some minor, non-speciﬁc immunoreactivity at higher molecular weights (indicated by the asterisk) in S5 from both wild-type and parkin knockout. (C) The graph
shows how BN gels were calibrated based on the relative mobilities of native protein size markers to determine the molecular weight (MW) of the parkin complex.
Markers, denoted by black circles, were thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), lactate dehydrogenase (140 kDa) and bovine serum
albumin (67 kDa). The dotted line indicates the estimated MWof the parkin complex. (D) In the left and middle panels, heating brain fraction S5 at 100  C in 1.5%
sodium dodecyl sulphate (SDS) for 10 min immediately prior to BN-PAGE disrupted the  110-kDa parkin complex and led to the appearance of monomeric parkin
(indicated by the arrow). In the rightmost panel, approximately 50 ng of puriﬁed recombinant parkin was analysed by BN-PAGE and Western blot with PRK109
without heat treatment or addition of SDS, revealing a band (indicated by the arrow) with apparent molecular weight ( 50 kDa) consistent with that of monomeric
parkin. (E) Omission of Triton X-100 from the extraction protocol did not change the native molecular mass of the parkin complex from brain or the amounto f
parkin extracted. Numbers to the left of (A), (B), (D) and (E) indicate MWs of the native protein size markers.
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Omission of Triton X-100 also did not diminish the amount of parkin
extracted (Fig. 2E), consistent with the previous ﬁnding that mouse
parkin is highly soluble and easily extracted from brain even in the
absence of detergents (Pawlyk et al., 2003).
As an independent approach, we determined the molecular mass of
native parkin by gel ﬁltration chromatography of fraction S in the
absence of detergents. Parkin eluted from the column as a single peak
with an estimated molecular weight of  105 kDa (Fig. 3), consistent
with the BN-PAGE results. Monomeric parkin was again undetectable.
The parkin gene is not only expressed in brain but also in other
tissues, especially heart and skeletal muscle (Kitada et al., 1998). To
ﬁnd out whether the components of the  110-kDa parkin complex
were also expressed outside the brain, we applied the protocol shown
in Fig. 1A to mouse heart and skeletal muscle. The apparent molecular
mass of parkin on native gels was similar in extracts from heart,
skeletal muscle and brain (Fig. 4), suggesting that none of the
components of the parkin complex was brain speciﬁc.
Next we performed immunoprecipitation experiments on brain
extracts using the parkin-speciﬁc monoclonal antibodies and separated
the immunoprecipitates by SDS–PAGE, in order to identify the
components of the parkin complex by silver staining of the gels and
mass spectrometry. However, comparison of silver-stained gels of
immunoprecipitates from wild-type and parkin-null brains failed to
reveal any speciﬁc bands (data not shown). This was possibly due to
low abundance of the parkin complex in brain, low afﬁnity of the
monoclonal parkin antibodies, or masking of speciﬁc bands on the gel
by the light or heavy chain bands of the immunoprecipitating
antibody.
As an alternative approach for identiﬁcation of the components of
the native parkin complex, we compared the migration of parkin in
glycerol gradients and native gels with that of previously published
parkin-binding partners. However, the reported parkin-interacting
proteins BAG5 (Kalia et al., 2004), CHIP (Imai et al., 2002), 14-3-3g
(Sato et al., 2006), hSel-10 (Staropoli et al., 2003) and Hsp70 (Imai
et al., 2002) migrated in characteristic, reproducible band patterns that
clearly differed from that of parkin (Fig. 5). By contrast, immuno-
reactivity for a-tubulin and b-tubulin (Yang et al., 2005), two proteins
with monomeric molecular masses of  50 kDa, partially overlapped
with the 110-kDa parkin band (Fig. 6A). One possible interpretation
was that the parkin band represented a stable complex of parkin with
monomeric tubulin. Alternatively, the overlap of immunoreactivity
could simply be due to the close proximity of the molecular weight of
the a⁄b-tubulin heterodimer to that of the parkin complex. To
discriminate between these two possibilities, we performed antibody
supershift experiments (Fig. 6B). If parkin and tubulin coexist in a
stable complex, incubation of extracts with anti-tubulin antibody
before BN-PAGE should change the migration of parkin due to
antibody binding to parkin–tubulin complexes (Yang et al., 2002;
Vandenberghe et al., 2005a). However, this was not the case, arguing
against the existence of a stable parkin–tubulin complex in these
extracts (Fig. 6B). This conclusion was further supported by the
similar migration pattern of tubulin from wild-type and parkin-null
brain extracts (Fig. 6C). Not unexpectedly, immunoreactivity for the
104-kDa protein CASK (Fallon et al., 2002) also partially overlapped
with the  110-kDa parkin band, but antibody supershift experiments
and comparison with parkin-null extracts did not show evidence for
the presence of a stable parkin–CASK complex (data not shown).
Other published parkin-binding proteins, such as Rpn10 (Sakata et al.,
2003), XAPC7 (Dachsel et al., 2005), UbcH7 (Imai et al., 2000;
Shimura et al., 2001), cullin-1 (Staropoli et al., 2003), DJ-1 (Baulac
et al., 2004), synphilin-1 (Chung et al., 2001), CDCrel-1 (Zhang et al.,
2000), a-synuclein (Shimura et al., 2001), p38 (Corti et al., 2003),
TRAF2 and IKKc (Henn et al., 2007), equally failed to show
detectable association with the parkin complex on native gels (data not
shown). We did not check the migration patterns of the recently
reported parkin interactors LRRK2 (Smith et al., 2005), RANBP2
(Um et al., 2006), Eps15 (Fallon et al., 2006) and ataxin-2 (Huynh
et al., 2007), because these proteins, with predicted molecular weights
Fig. 3. Demonstration of the parkin complex in brain by gel ﬁltration chromatography. (A) Fraction S prepared in the absence of detergents was applied to a gel
ﬁltration column. Fractions of 0.5 mL were eluted from the column and fractions 11–70 were analysed with dot blot for parkin using the PRK109 antibody. Fraction
numbers are indicated to the left of the blot. Molecular weights (MWs) indicate the elution patterns of the protein size markers thyroglobulin (669 kDa), ferritin
(440 kDa), lactate dehydrogenase (140 kDa), bovine serum albumin (67 kDa), vitamin D-binding protein (55 kDa) and protein phosphatase 2A phosphatase
activator (36 kDa). (B) Calibration graph of the gel ﬁltration column. The black circles denote the protein size markers. Kav ¼ (Ve ) Vo) ⁄ (Vt ) Vo), where
Ve ¼ elution volume, Vo ¼ void volume and Vt ¼ total column volume. The dotted line indicates the estimated MW of the parkin complex.
Fig. 4. Formation of the  110-kDa parkin complex is conserved across
tissues. S fractions were prepared from mouse heart, skeletal muscle and brain
(Br.). The samples were analysed with glycerol gradient centrifugation,
BN-PAGE and Western blotting with the monoclonal anti-parkin antibody
PRK8. The arrow indicates the position of the  110-kDa parkin complex.
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were too large to be subunits of the  110-kDa parkin complex.
The  110-kDa parkin complex is not a parkin homodimer
We considered the possibility that the  110-kDa parkin complex
might be a parkin homodimer. However, this was highly unlikely for
four reasons. First, the apparent molecular mass ( 50 kDa) of puriﬁed
recombinant parkin on native gels (Fig. 2D) already suggested that
parkin does not easily form homodimers. Second, parkin over-
expression experiments in cell lines argued against a homodimeric
composition of the parkin complex (Fig. 7). Endogenous parkin was
not detectable with our BN-PAGE assay in untransfected COS1,
SH-SY5Y, CHO or HEK-293 cells (data not shown). However, when
we transfected parkin in COS1, SH-SY5Y or CHO cells, the protein
accumulated predominantly as a monomer, with only minor formation
of the  110-kDa complex (Fig. 7A–C). This strongly suggested that
the  110-kDa complex was not a parkin dimer, but rather contained
components that were present in limiting amounts in transfected
COS1, SH-SY5Y and CHO cells. Interestingly, the abundance of the
 110-kDa complex (relative to that of the parkin monomer) was
dramatically higher in transfected HEK-293 cells (Fig. 7D) than in
COS1, SH-SY5Y or CHO cells, suggesting that HEK-293 cells
expressed higher endogenous levels of the binding partners required
for complex formation.
Third, we also varied the transfection level of parkin in COS1 cells
(Fig. 7E and F). With higher total parkin expression levels, there was
relatively little change in the amount of complex, but there was a clear
increase in the amount of monomer. Thus, formation of the  110-kDa
complex again appeared to be limited by the endogenous levels of the
required parkin-binding partners.
Finally, partial denaturation experiments did not support a
(homo)dimeric structure of the parkin complex. Heating extracts from
brain (Fig. 8A) or transfected COS1 cells (Fig. 8B) to 65  C (instead
of 100  C as in Fig. 2D) in 1.5% SDS led to partial dissociation of the
parkin complex and the appearance of three parkin bands with
estimated molecular masses of approximately 80, 60 and 50 kDa. The
most parsimonious explanation for this observation would be that the
 60-kDa band represented a complex of parkin with a protein other
than parkin itself, the  80-kDa band reﬂected the association of a
third component and the  110-kDa band arose from the addition of
yet another subunit. According to this simple model, the  110-kDa
complex would be a tetramer. Alternatively, it was also possible that,
for example, the  60-kDa band represented a complex of parkin with
more than one other protein, in which case the  110-kDa complex
Fig. 5. Known parkin-interacting proteins do not show detectable association
with parkin on native gels. (A–F) S and P fractions from brain were separated
by glycerol gradient centrifugation and BN-PAGE, followed by Western
blotting for the protein indicated. The dotted ellipses indicate the position of the
parkin band, as determined by reprobing each blot with anti-parkin.
Fig. 6. Lack of a detectable stable complex of parkin with tubulin. (A) Frac-
tion S from brain was separated by glycerol gradient centrifugation, and
fractions S4–S6 were analysed by BN-PAGE and Western blotting for parkin,
a-tubulin or b-tubulin (b-Tub.). The dotted ellipses indicate the position of the
parkin band, as determined by reprobing each blot with anti-parkin. In the
rightmost panel, fraction S was boiled in 1.5% sodium dodecyl sulphate (SDS)
for 10 min before BN-PAGE to identify the monomeric tubulin band.
(B) Fractions S4–S6 were incubated for 90 min with 5 lg of control rabbit
IgG, rabbit anti-a-tubulin (Tub. Ab), or buffer alone (Tris) before BN-PAGE.
After Western blotting (WB) with mouse anti-a-tubulin (left panel), the blot was
stripped and reprobed with mouse anti-parkin (right panel). Pre-incubation with
polyclonal anti-a-tubulin fully shifted the a-tubulin bands to higher molecular
weights due to antibody binding and cross-linking of tubulin complexes (left
panel), but did not shift the parkin band (right panel). (C) The migration
pattern of native b-tubulin from parkin knockout (KO) brain is similar to that in
the wild-type extracts shown in (A).
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suggested that the  110-kDa complex was at least a tetramer. In
any case, the results shown in Fig. 8 were not consistent with the
 110-kDa complex being a parkin homodimer.
PD-linked parkin mutations compromise parkin complex
formation
Many pathogenic parkin mutations have been shown to cause a loss
of parkin function by impairing its solubility, stability or catalytic
activity (Henn et al., 2005; Sriram et al., 2005). However, a subset of
PD-linked parkin mutations (including the A82E, K161N, K211N
and R256C missense mutations) have little impact on parkin
solubility, stability or interaction with known binding partners or on
its intrinsic catalytic activity in a cell-free system (Hampe et al.,
2006). The pathogenic mechanism of these mutations thus remains
elusive. We therefore explored whether the A82E, K161N, K211N
and R256C mutations disrupted the  110-kDa complex. We trans-
fected wild-type, A82E, K161N, K211N and R256C parkin cDNA
into COS1 cells to determine the relative amounts of parkin complex
and monomer. Importantly, Triton-soluble parkin levels were similar
for the wild-type, A82E, K161N, K211N and R256C variants, as
shown by parallel control experiments (Fig. 9C and D), thus
precluding confounding effects of parkin expression levels on the
observed complex⁄monomer ratios. Interestingly, each of the four
Fig. 7. Overexpressed parkin accumulates predominantly as a monomer in
several cell lines. (A) COS1 cells were transiently transfected with parkin and
extracted in 1% Triton X-100, followed by glycerol gradient centrifugation of
the extract. Glycerol gradient fractions 2–11 were analysed by BN-PAGE and
immunoblotting for parkin. Upon overexpression parkin migrated as a
monomer (indicated by the arrow on the left of the ﬁrst panel). After more
prolonged ﬁlm exposure, a small amount of the  110-kDa complex was
detected, as illustrated by comparison with the endogenous parkin band
(indicated by the arrowhead) from brain (Br.). (B–D) SH-SY5Y (B), CHO
(C) and HEK-293 (D) cells were transiently transfected with parkin and
extracted in 1% Triton X-100. Glycerol gradient fractions 2–6 were analysed by
BN-PAGE and immunoblotting for parkin. (B) The results of both brief and
more prolonged ﬁlm exposure are shown. In the rightmost panel of (B), total
Triton-soluble extract from transfected SH-SY5Y cells was boiled in 1.5% SDS
for 10 min immediately before BN-PAGE to identify the monomeric parkin
band. The arrows and arrowheads indicate monomeric parkin and the  110-
kDa parkin complex, respectively. (E) Either 30 or 250 ng of parkin cDNA
was transfected per cm
2 of COS1 cell culture. For each transfection condition,
20 lg of total protein extract was examined by sodium dodecyl sulphate
(SDS)–PAGE and Western blotting, showing different total parkin expression
levels. The mobility of a 50-kDa molecular weight marker is shown on the left
of the blot. (F) Extracts of COS1 cells transfected with either 30 or 250 ng of
parkin cDNA per cm
2 were analysed by glycerol gradient centrifugation, and
fractions 3–5 were subjected to BN-PAGE and parkin immunoblotting to
visualize monomer (arrow) and  110-kDa complex (arrowhead). In the right
panel, total Triton-soluble extract from COS1 cells transfected with
250 ng ⁄ cm
2 of parkin cDNAwas boiled in 1.5% SDS for 10 min immediately
before BN-PAGE to identify the monomeric parkin band. When only
10 ng ⁄ cm
2 of parkin cDNA was transfected, the protein was not detectable
with the glycerol gradient centrifugation and BN-PAGE assay (not shown).
Fig. 8. Partial dissociation of the parkin complex. (A) Heating fraction S
from brain to 65  C for 10 min in 1.5% sodium dodecyl sulphate (SDS) before
BN-PAGE led to the appearance of three parkin bands (indicated by the
arrows), suggesting that the  110-kDa complex was at least a tetramer. In the
rightmost panel, fraction S was heated to 100  C in 1.5% SDS for 10 min
before BN-PAGE to dissociate the parkin complex completely and identify the
position of the monomeric parkin band. (B) COS1 cells were transiently
transfected with parkin and extracted in 1% Triton X-100. The cell extracts
were treated in the same way as the brain extracts in (A).
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complex (Fig. 9A and B). Quantitatively, the A82E, K161N, K211N
and R256C mutations caused a  40%,  60%,  50% and  30%
reduction, respectively, of the amount of parkin complex relative to
total parkin (Fig. 9B). Given the similar soluble parkin expression
levels (Fig. 9C and D), the differences in parkin complex⁄monomer
ratio between wild-type and mutant proteins indicated a reduced
intrinsic ability of the mutants to form the  110-kDa complex. We
also examined the R275W parkin variant, which was previously
shown to have reduced, but non-zero, solubility in Triton X-100
(Hampe et al., 2006). The Triton-soluble level of R275W parkin was
indeed lower than that of the other variants (Fig. 9C and D). A small
amount of R275W parkin monomer was detected, but no complex
was observed (Fig. 9A).
Discussion
Mutations in the parkin gene are the most common known cause of
autosomal recessive early onset PD (Lu ¨cking et al., 2000). Seminal
work has identiﬁed an E3 ubiquitin ligase function for parkin (Imai
et al., 2000; Shimura et al., 2000; Zhang et al., 2000). However, it is
unclear whether parkin is a monomer or functions in a larger protein
complex. To address this issue, we have investigated parkin under
native conditions. Our study has led to two important conclusions.
First, parkin exists in mouse brain and muscle as part of a stable, non-
covalent, heteromeric complex with a molecular mass of  110 kDa.
Surprisingly, monomeric parkin is not detectable in vivo. Second,
PD-linked parkin mutations signiﬁcantly compromise formation of
this complex.
Fig. 9. Comparison of  110-kDa complex formation between wild-type (WT) parkin and PD-linked parkin variants. COS1 cells were transiently transfected with
70 ng ⁄ cm
2 of WTor R256C mutant parkin cDNA, 50 ng ⁄ cm
2 of A82E or K161N parkin cDNA, 30 ng ⁄ cm
2 of K211N cDNA and 120 ng ⁄ cm
2 of R275W cDNA.
(A) Transfected COS1 cells were extracted in 1% Triton X-100, followed by glycerol gradient centrifugation of the extracts. Fractions 2–6 of the gradient were
analysed by BN-PAGE and parkin immunoblotting to visualize monomer (arrowhead) and  110-kDa complex (arrow). (B) In the experiments shown in (A), the
amounts of parkin complex and parkin monomer were quantiﬁed. The graph represents the amount of parkin complex, expressed as a percentage of the sum of parkin
complex and monomer. Asterisks denote signiﬁcant difference (P<0.05) from WT. (C and D) In parallel with each of the experiments shown in (A and B), 15 lgo f
Triton-soluble protein extract was analysed with SDS–PAGE and parkin immunoblotting to compare soluble parkin protein levels between WTand mutant variants.
At the low signal intensity of the blots shown in (C), parkin appeared as a doublet due to the presence of an N-terminally truncated parkin species generated through
an internal translation initiation site (Henn et al., 2005). No endogenous parkin signal could be observed by SDS–PAGE in untransfected (Untransf.) COS1 cells (C),
except after very prolonged ﬁlm exposures (not shown). The graph in (D) shows SDS–PAGE and Western blot quantiﬁcation of the Triton-soluble parkin levels.
Within each experiment, the level of the parkin mutants was normalized to that of WT parkin. There were no signiﬁcant differences in soluble parkin levels between
WT, A82E, K161N, K211N or R256C (P ¼ 0.96 by one-way anova).
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ageing human brain (Pawlyk et al., 2003) and that oxidative stress can
induce parkin aggregation (Winklhofer et al., 2003; LaVoie et al.,
2005; Wang et al., 2005). However, the  110-kDa parkin complex
detected in this study is clearly not an aggregate, for three reasons.
First, a parkin aggregate would be expected to be poorly soluble and to
be extractable only in harsher detergents, whereas the  110-kDa
parkin complex is highly soluble and easily extracted from mouse
brain even in the absence of detergents. Second, aggregated parkin
would be expected to appear on the gel as a ladder or smear of high-
molecular-weight species rather than as a discrete band of  110 kDa.
Third, conditions of transient overexpression generally increase the
tendency of proteins to aggregate due to molecular crowding.
However, upon overexpression in COS1, SH-SY5Y or CHO cells
parkin accumulated in monomeric form with only limited formation of
the  110-kDa parkin complex. This led to the conclusion that the
 110-kDa complex was not an aggregate, but rather a complex of
parkin with other proteins that were available in limiting amounts in
the transfected cells.
In the present study previously reported parkin-interacting proteins
did not show detectable association with the parkin complex after
glycerol velocity gradient centrifugation and BN-PAGE. However,
this assay is primarily designed to demonstrate interactions between
stoichiometric components of stable protein complexes. The assay is
less appropriate for detection of transient interactions (e.g. enzyme–
substrate interactions) or of stable interactions that involve only a
small percentage of the parkin molecules. Also, some parkin
interactions may be weak and may therefore be disrupted during the
prolonged centrifugation and electrophoresis procedures. Therefore,
the lack of observable co-migration of the parkin complex and known
parkin-binding proteins does not argue against the authenticity of the
previously reported parkin interactions, and the present study by no
means implies that parkin does not bind to its published partners.
Nevertheless, our ﬁndings raise the tantalizing possibility that some of
the most stable binding partners of parkin still remain to be identiﬁed.
It is tempting to speculate that the as yet unidentiﬁed constituents of
the  110-kDa complex may be required for optimal parkin function.
For example, the other subunits could control parkin stability,
subcellular localization, substrate speciﬁcity or ubiquitin ligase
activity (including the preference of parkin for mono- vs polyubiq-
uitination). If so, genes encoding the other components of the complex
would be attractive candidates for inherited forms of parkinsonism and
other neurodegenerative syndromes. Intriguingly, we observed that the
PD-linked parkin mutants A82E, K161N, K211N and R256C have a
signiﬁcantly reduced ability to form the  110-kDa complex. If
complex formation is indeed necessary for proper functioning of
parkin in cells, the observed reduced capacity for complex formation
will explain the hitherto poorly understood pathogenic nature of these
mutations (Hampe et al., 2006). Also, this would resolve the paradox
that the K161N and R256C mutants have less ubiquitination activity
than wild-type when expressed in cells (Chung et al., 2001; Sriram
et al., 2005), while possessing normal intrinsic ubiquitination activity
in a cell-free system (Hampe et al., 2006).
Interestingly, the absence of detectable monomeric parkin in brain
and muscle suggests that endogenous expression levels of parkin are
limiting for formation of this complex in vivo. This would make this
complex exquisitely vulnerable to even slight reductions in the
availability of soluble parkin that may result from parkin mutations
(Winklhofer et al., 2003; Henn et al., 2005; Sriram et al., 2005;
Hampe et al., 2006), as illustrated by our experiments with the
R275W mutant. Cellular stress conditions (Winklhofer et al., 2003;
LaVoie et al., 2005; Wang et al., 2005) and normal ageing (Pawlyk
et al., 2003) are also known to impair parkin solubility and would
therefore also be predicted to reduce the level of the parkin
complex.
Further biochemical puriﬁcation of the native parkin complex will
be required to elucidate the identity of its components and to
determine how they control parkin function. An analogy can be made
with the identiﬁcation of the subunits of the Alzheimer’s disease-
linked presenilin complex. One of the ﬁrst indications that the
presenilins functioned as part of a stable, oligomeric protein complex
was that glycerol velocity gradient centrifugation suggested a much
higher native molecular weight for the presenilins than expected based
on their amino acid sequence (Capell et al., 1998). It has taken several
years and a variety of experimental approaches from multiple
laboratories to identify nicastrin, anterior pharynx defective-1
(Aph-1) and presenilin enhancer-2 (Pen-2) as the additional constit-
uents of the functional c-secretase complex (De Strooper, 2003).
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